Navigation Links
Unique nerve-stimulation device proves effective against epilepsy
Date:3/18/2009

Epilepsy is a common medical condition characterized by convulsions and short periods of confusion. It affects more than 50 million people worldwide. But intractable epilepsy, which affects more than 1 million Americans and is often resistant to drug treatment and surgery, is arguably worse.

But in a just completed clinical trial, a unique nerve-stimulation treatment for intractable epilepsy reduced the number of seizures by more than 50 percent. In the March edition of the journal Neurology, UCLA neurology professor Christopher M. DeGiorgio and colleagues report the results of the long-term pilot trial, which demonstrated the effectiveness of the new treatment, called trigeminal nerve stimulation (TNS).

The results, though preliminary, are very encouraging, DeGiorgio said. Those participating in the trial for three months saw a 66 percent reduction in the number of seizures, those participating for six months saw a 56 percent reduction and those who completed one year saw a 59 percent reduction in seizures. One of the subjects who participated for a full year had a 90-percent reduction in seizures.

The trigeminal nerve extends into the brain from the face and forehead and is known to play a role in seizure inhibition. The stimulator, about the size of a large cell phone, attaches to a belt or can slip into a pocket. Two wires from the stimulator are passed under the clothing and connected to electrodes attached to the forehead by adhesive. The electrodes, which can be covered by a cap or scarf, transmit an electrical current to the nerve.

"People with intractable epilepsy who have continuing seizures are often drug-resistant," DeGiorgio said. "In addition, anti-seizure drugs can have significant side effects on thinking and alertness."

Epilepsy brain surgery can be very effective, he said, but some patients are not ideal candidates because there is no single focal point in the brain for their seizures.

A larger clinical trial to further test for safety and effectiveness is now underway. The investigators hope that eventually a device can be permanently implanted above the eyebrow that would stimulate the trigeminal nerve and replace the external device.

"TNS is a promising alternative mode of neurostimulation because the trigeminal nerve can be stimulated in minimally invasive fashion," DeGiorgio said. "The major branches of the trigeminal nerve in the face are located close to the surface of the skull; that allows physicians to assess response prior to permanent implantation of a future device.

"For all of these reasons, we need to find non-drug and non-surgical alternatives," he said. "The results of our study are very encouraging and support further investigation into the safety and efficacy of TNS."


'/>"/>

Contact: Mark Wheeler
mwheeler@mednet.ucla.edu
310-794-2265
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Unique role for blood formation gene identified
2. New Seminar Series from Activator Methods Teaches Doctors a Unique Approach to Improving Nations Chiropractic Care: Focus on the Patients
3. Blue Cross and Blue Shield Association Nationally Recognized by BusinessWeek and AARP for Creating a Unique Workplace Environment for New and Mature Employees
4. Frutarom Acquires Gewurzmuller, a Company Specializing in Unique Savory Flavors
5. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
6. Graduates of Unique New Labor/Management Healthcare Workforce Training Program Honored Today in Oakland
7. Deep Breeze Ltd. Launches Unique Non-Invasive, Radiation-Free Pulmonary Imaging System in the U.S.
8. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
9. The Lilly MDR-TB Partnership Provides Unique Model for Fight Against Multidrug-Resistant Tuberculosis in South Africa
10. Franco e Rizzi Offers Low-Cost Weight Loss Surgery (WLS) With Unique Price Guarantee
11. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... Maryland (PRWEB) , ... June 24, 2016 , ... ... Angels is actively feeding the Frederick area economy by obtaining investment capital for ... over the past 2½ years that have already resulted in more than a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: